Cathie Wood, of ARK Genomic Revolution ETF(NYSE: ARKG) explains the multi-trillion dollar opportunity in the Genomics Revolution: CAR-T, CRISPR, and DNA Sequencing
Related Articles
First Patient in CytoDyn’s (OTC: CYDY) Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size
November 13, 2019
admin
Healthcare, Newsmakers
Comments Off on First Patient in CytoDyn’s (OTC: CYDY) Triple-Negative Metastatic Breast Cancer Trial Shows Significant Reduction in Circulating Tumor Cells (CTC) and Reduced Tumor Size
Breakthrough Therapy designation filing possible if more patients show similar positive results VANCOUVER, Washington, Nov. 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 […]
Marc Cuban and Kyle Bass Talk Investing Strategy (+AI, Robotics & Bitcoin)
March 26, 2018
admin
Investing Strategy, Smart Money
Comments Off on Marc Cuban and Kyle Bass Talk Investing Strategy (+AI, Robotics & Bitcoin)
Hedge Fund legend Kyle Bass interviews Marc Cuban. Talking Investing Strategy (+AI, Robotics & Bitcoin) Did you enjoy this article? Join our FREE Newsletter! Thank you for subscribing. Something went wrong. I agree to have […]
CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies
November 20, 2019
admin
Newsmakers
Comments Off on CytoDyn’s (OTC: CYDY) Lead Product Candidate Leronlimab (PRO 140) Inhibits Colon Carcinoma Metastases to Liver and Lung in Preclinical Studies
CytoDyn will file for expanded access IND for patients with pancreatic, prostate, lung, breast, liver and melanoma cancers VANCOUVER, Washington, Nov 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology […]